![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
University of Iowa National Institute of Neurological Disorders and Stroke (NINDS) |
---|---|
Information provided by: | National Institute of Neurological Disorders and Stroke (NINDS) |
ClinicalTrials.gov Identifier: | NCT00051324 |
The purpose of this trial is to study early brain and behavioral changes in people who have the gene expansion for Huntington's disease, but are currently healthy and have no symptoms.
Condition |
---|
Huntington Disease |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | Neurobiological Predictors of Huntington's Disease Trial |
Plasma retained from 2000-2007. Urine, plasma and cell lines to be acquired and retained 2008-2013.
Estimated Enrollment: | 1100 |
Study Start Date: | August 2002 |
Estimated Study Completion Date: | August 2013 |
Estimated Primary Completion Date: | August 2013 (Final data collection date for primary outcome measure) |
Huntington's Disease (HD) is an inherited disease that causes changes in a person's ability to control movements, thinking, and feelings. The intent of this study is to learn more about the beginning changes in thinking skills, emotional regulation, and brain structure and function as a person begins the transition from health to HD.
Preliminary studies indicate that people with HD may have marked decline before an actual diagnosis. This study will help reveal the earliest indicators of the disease and what factors influence the age at which a person carrying the gene develops the disease. It is necessary to get information on the early stages of HD in order to develop drugs that can slow or postpone the onset of HD. The investigators hope this study will provide essential information for future trials of experimental drugs for HD.
During this 4-year study, participants will undergo several detailed tests, including MRI scans of the brain, cognitive assessments, physical exams, and neurological and psychiatric testing.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
People at risk for HD, who have been tested for the HD gene mutation, and who have not been diagnosed with symptoms of HD.
Inclusion Criteria:
Exclusion Criteria:
Contact: Stacie Vik | 319-353-3716 | Stacie-vik@uiowa.edu |
Principal Investigator: | Jane S. Paulsen, Ph.D. | University of Iowa |
Responsible Party: | University of Iowa ( Jane Paulsen, PhD, PREDICT-HD Principal Investigator ) |
Study ID Numbers: | R01NS40068 |
Study First Received: | January 8, 2003 |
Last Updated: | December 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00051324 |
Health Authority: | United States: Federal Government |
Huntington's disease Huntington disease HD |
Ganglion Cysts Huntington disease Basal Ganglia Diseases Central Nervous System Diseases Brain Diseases Neurodegenerative Diseases Dyskinesias Cognition Disorders Chorea |
Delirium, Dementia, Amnestic, Cognitive Disorders Heredodegenerative Disorders, Nervous System Genetic Diseases, Inborn Mental Disorders Movement Disorders Dementia Huntington Disease Delirium |
Nervous System Diseases |